Cellular Therapy in Hematology and Oncology: Expert Guidance for Clinical Practice

Deerfield, IL US
September 21, 2024

This CME-accredited activity Cellular Therapy in Hematology and Oncology: Expert Guidance for Clinical Practice features leading experts in hematologic malignancies and cellular therapies who will provide a comprehensive overview of current and emerging strategies for the management of lymphoma, myeloma, acute leukemias, and solid tumors with a focus in the use of cellular therapies. The goal of this activity is to improve the knowledge and competence of learners to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with hematologic malignancies and to describe potential future applications of cellular therapy in solid tumors. The activity will use a mix of didactic lectures and case-based discussions to highlight areas of debate between cellular therapy and non-cellular therapy in the treatment of these diseases. Expert faculty will aim to place the role of different therapeutic agents in a clinical context and discuss how to utilize these therapeutic options to effectively contribute to patient care. This conference is designed to provide physicians, physician assistants, nurse practitioners, pharmacists, nurses, and other healthcare professionals with the latest updates in the field. It will highlight a multidisciplinary approach and the integration of new advances in patient-centered care.

The symposium will augment healthcare providers’ foundation of knowledge and clinical competence in several areas:

  • Providing a review of existing clinical evidence supporting approved Chimeric Antigen Receptor T-cell (CAR T) therapies in the care of patients with B-cell Acute Lymphoblastic Leukemia (B-ALL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Mantle Cell Lymphoma (MCL), and Multiple Myeloma (MM)
  • Describing the role of non-cellular therapies in B-ALL, DLBCL, FL, MCL, and MM
  • Identify challenges to the delivery of cellular therapies and provide a discussion on how such barriers may be addressed
  • Discussing novel investigational approaches of cellular therapy in acute myeloid leukemias and solid tumors

Organizing Committee

Conference Director: 

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Binod Dhakal, MD - Froedtert & the Medical College of Wisconsin

Syed A. Abutalib, MD - Aurora St. Luke’s Medical Center

 

Target Audience

  • Hematologists/Medical Oncologists 
  • Oncology fellows
  • Oncology nurses
  • NPs/PAs
  • Oncology pharmacists

Hotel Information

Coming soon

 

Learning Objectives

Upon successful completion of this educational activity, participants will be able to:

  • Review indications and outcomes of approved cellular therapies in hematologic malignancies
  • Identify emerging CAR-based therapies in hematologic malignancies and solid tumors
  • Identify and manage complications after cellular therapy
  • Incorporate into practice knowledge about financial toxicity and quality of life after CAR T-cell therapies
  • State the financial, physical, and other barriers, review strategies to navigate these factors to optimize the management of patients with cellular therapies

GLOBAL ONCOLOGY PROJECT

Click this link to learn more about our ongoing project building a 200-bed cancer hospital in Nepal: https://binayfoundation.org/cancer-hospital/

Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
04/19/2024
Course expires: 
12/31/2024
Event starts: 
09/21/2024 - 8:00am PDT
Event ends: 
09/21/2024 - 4:00pm PDT
Cost:
$350.00

September 21st, 2024

All times are listed in Central Daylight Time (CDT)

07:00 AM – 08:00 AM  Registration, Breakfast, & Exhibits


08:00 AM – 08:05 AM  Welcome

08:05 AM – 08:20 AM  Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA


08:20 AM – 09:50 AM  Session 1 - Plasma Cell Disorders 

Session Chair : Binod Dhakal, MD

08:20 AM – 08:35 AM  Sequencing Autologous Transplant and CAR T Cell Therapy in Early Relapse

08:35 AM – 08:50 AM  Sequencing BsAb and CAR T Cell Therapy in Late Relapses - Sridevi Rajeeve, MD

08:50 AM – 09:05 AM  MRD Evaluation and Implication for Practice

09:05 AM – 09:20 AM  Role of Transplant and Maintenance Therapy in AL Amyloidosis - Anita D'Souza MD

09:20 AM – 09:50 AM  Discussion


09:50 AM – 10:20 AM  Break & Exhibits


10:20 AM – 11:50 AM  Session 2 - Lymphomas

Session Chair:

10:20 AM – 10:35 AM  Autologous vs. Allogeneic vs. CAR in B- NHL

10:35 AM – 10:50 AM  Autologous Transplant and CAR T in MCL

10:50 AM – 11:05 AM  Transplantation in T-NHL

11:05 AM – 11:20 AM  CAR T Cell Therapy in CLL

11:20 AM – 11:50 AM  Discussion 


11:50 AM – 12:50 PM  Lunch & Exhibits


12:50 PM –  02:20 PM  Session 3 - Acute Leukemias and MPN 

Session Chair: Syed A. Abutalib, MD

12:50 PM – 01:05 PM  Allogeneic Transplant in AML - Michael Grunwald MD

01:05 PM – 01:20 PM  Treatment of Relapsed Adult B-ALL - Anand Patel MD

01:20 PM – 01:35 PM  MRD Timing and Implication in Adult Acute Leukemias

01:35 PM – 01:50 PM  Allogeneic Transplants in MPN

01:50 PM – 02:20 PM  Discussion 


02:20 PM – 02:50 PM  Break & Exhibits


02:50 PM – 04:20 PM  Session 4 - Special Issues In Allogeneic Transplant

Session Chair:

02:50 PM – 03:05 PM  Updates in cGvHD - Catherine J Lee MD

03:05 PM – 03:20 PM  HLA Mismatch and PTCy

03:20 PM – 03:35 PM  DLI and CD34 Boost – Why and When? - Bipan Savani MD

03:35 PM – 03:50 PM  Post-Transplant Immunosuppressive Therapy in 2024

03:50 PM – 04:20 PM  Discussion 


04:20 PM  Adjourn

Hyatt Regency Deerfield
1750 Lake Cook Rd
Deerfield, IL 60015
United States

IDENTIFICATION AND MITIGATION OF POTENTIAL CONFLICT OF INTERESTS:

All conflict of interest has been identified and mitigated for individuals in control of contents.

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Speaker/Topic Presenter(s)

Anand Patel, Assistant Professor of Medicine; Medical Director, Inpatient Leukemia Service

has a financial relationship (Other) with AbbVie;.
has a financial relationship (Grant Or Contract) with Sumitumo;.
has a financial relationship (Grant Or Contract) with Kronos Bio;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Other) with Bristol Myers Squibb;.
has a financial relationship (Other) with Sobi;.

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.